Calithera Biosciences, Inc.
CALA · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $9,750 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $1,385 | $1,434 | $1,870 | $1,845 |
| Gross Profit | -$1,385 | $8,316 | -$1,870 | -$1,845 |
| % Margin | – | 85.3% | – | – |
| R&D Expenses | $28,533 | $103,374 | $71,015 | $76,290 |
| G&A Expenses | $13,541 | $20,853 | $20,372 | $16,605 |
| SG&A Expenses | $12,156 | $20,853 | $20,372 | $16,605 |
| Sales & Mktg Exp. | -$1,385 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$1,634 | -$1,870 | $0 |
| Operating Expenses | $40,689 | $122,593 | $89,517 | $92,895 |
| Operating Income | -$42,074 | -$114,277 | -$91,387 | -$92,895 |
| % Margin | – | -1,172.1% | – | – |
| Other Income/Exp. Net | $2,424 | -$811 | $1,250 | $3,035 |
| Pre-Tax Income | -$39,650 | -$115,088 | -$90,137 | -$89,860 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18,866 | -$115,088 | -$88,523 | -$86,346 |
| % Margin | – | -1,180.4% | – | – |
| EPS | -7.94 | -31.16 | -26.2 | -36.5 |
| % Growth | 74.5% | -18.9% | 28.2% | – |
| EPS Diluted | -7.94 | -31.16 | -26.2 | -36.5 |
| Weighted Avg Shares Out | 4,992 | 3,693 | 3,441 | 2,366 |
| Weighted Avg Shares Out Dil | 4,992 | 3,693 | 3,441 | 2,366 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $345 | $1,250 | $3,035 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,385 | $1,434 | $1,870 | $1,845 |
| EBITDA | -$38,265 | -$113,654 | -$88,267 | -$88,015 |
| % Margin | – | -1,165.7% | – | – |